Tag: Sanofi

dupilumab

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
AR101+dupilumab

Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
AR101+dupilumab

Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...

Study scheduled to commence next week.
dupilumab

Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...

"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
AR101

Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate

The company announces their timeline for continued progress toward an FDA approved standardized therapy.
Peanut Therapy

Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy

More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
Kaleo Booth

Auvi-Q Takes Center Stage at School Nurse Conference

One example of the changing market dynamics for epinephrine auto-injectors in light of recent developments.
Mylan Chairman Robert Coury and CEO Heather Bresch

Mylan’s Chairman Was Paid $97.6 Million

Despite 2016 being a year when everything seemed to implode for the marketer of EpiPen.
Sanofi

Sanofi Files Suit Against Mylan for Anti-Competitive EpiPen Strategy

More legal troubles for the embattled marketer of EpiPen.

Auvi-Q Goes On Sale Today with a Bold Pricing and Distribution...

Innovation and participation by insurers will be key to the successful reintroduction of the device.

Connect with Us

36,531FansLike
94FollowersFollow
342FollowersFollow
2,523FollowersFollow
5,339FollowersFollow
37SubscribersSubscribe